Eye Inflammation Treatment Market
Eye inflammation, also known as ocular inflammation, is a disorder marked by the swelling of one or more eye regions and can be brought on by a number of different things, from minor irritation to specific illnesses. Eye Inflammation is classified according to the part of the eye that has been affected. Scleritis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, and Panuveitis are the different classifications. Panuveitis is a general word for an inflammation that affects the entire eye.
Eye inflammation is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides.
Market Dynamics
Increasing prevalence of autoimmune disorders is also expected to benefit in growth of the global eye inflammation treatment market, over the forecast period. For instance, according to a study published in February 2019 by National Multiple Sclerosis Society, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S. Multiple sclerosis is a disease that reasons inflammation and damage to the optic nerve that cases optic neuritis. Optic neuritis as an early sign of multiple sclerosis. Optic neuritis causes pain in eye, vision loss in one eye, etc. Steroid are used as a medication to reduce inflammation in the optic nerve, which is expected to drive the global eye inflammation market.
Moreover, advanced treatment of eye disease is expected to propel the growth of global eye inflammation treatment market, over the forecast period. For instance, according to data published on November 04, 2021, by American Academy of Ophthalmology, new dry eye treatments may be more effective than existing ones. Modern treatments for eye disease include lifestyle changes, a nasal spray, punctual plugs, anti-inflammatory medications, deep-cleaning devices, and specialized contact lenses. Currently available medications for the treatment of dry eye disease, approved by the U.S. Food and Drug Administration are Tyrvaya, Restasis, Cequa, Xiidra and Eysuvis.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 31 market data tables and 41 figures on "Global Eye Inflammation Treatment Market” - Forecast to 2030.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients